Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artivion Inc (AORT)

Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,117,146
  • Shares Outstanding, K 47,184
  • Annual Sales, $ 388,540 K
  • Annual Income, $ -13,360 K
  • EBIT $ 18 M
  • EBITDA $ 42 M
  • 60-Month Beta 1.65
  • Price/Sales 5.77
  • Price/Cash Flow 56.94
  • Price/Book 4.83

Options Overview Details

View History
  • Implied Volatility 59.47% ( -0.24%)
  • Historical Volatility 27.19%
  • IV Percentile 51%
  • IV Rank 50.92%
  • IV High 94.78% on 04/08/25
  • IV Low 22.85% on 01/22/25
  • Put/Call Vol Ratio 0.11
  • Today's Volume 21
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 186
  • Open Int (30-Day) 270

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.14
  • Number of Estimates 1
  • High Estimate 0.14
  • Low Estimate 0.14
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.30 +14.17%
on 10/08/25
47.69 -5.91%
on 11/06/25
+4.36 (+10.76%)
since 10/07/25
3-Month
38.05 +17.92%
on 08/08/25
47.69 -5.91%
on 11/06/25
+12.17 (+37.22%)
since 08/07/25
52-Week
21.97 +104.23%
on 04/09/25
47.69 -5.91%
on 11/06/25
+15.89 (+54.83%)
since 11/07/24

Most Recent Stories

More News
AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook

AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook

AORT : 44.87 (-5.54%)
Artivion: Q3 Earnings Snapshot

Artivion: Q3 Earnings Snapshot

AORT : 44.87 (-5.54%)
Artivion’s (NYSE:AORT) Q3 Sales Top Estimates

Artivion’s (NYSE:AORT) Q3 Sales Top Estimates

AORT : 44.87 (-5.54%)
Artivion Reports Third Quarter 2025 Financial Results

Third Quarter Highlights:

AORT : 44.87 (-5.54%)
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial

ATLANTA , Nov. 6, 2025 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient...

AORT : 44.87 (-5.54%)
Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings

Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings

AORT : 44.87 (-5.54%)
Artivion to Participate in the Stifel 2025 Healthcare Conference

ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT),  a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the...

AORT : 44.87 (-5.54%)
3 Healthcare Stocks We Find Risky

3 Healthcare Stocks We Find Risky

UFPT : 226.11 (+1.50%)
HAE : 68.36 (+1.86%)
AORT : 44.87 (-5.54%)
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results

ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial...

AORT : 44.87 (-5.54%)
Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way

Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way

AORT : 44.87 (-5.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Artivion Inc. is a medical device company. It focused on developing simple, elegant solutions which address cardiac and vascular surgeons. The company's group of products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts and surgical sealants....

See More

Key Turning Points

3rd Resistance Point 49.29
2nd Resistance Point 48.34
1st Resistance Point 46.60
Last Price 44.87
1st Support Level 43.92
2nd Support Level 42.97
3rd Support Level 41.23

See More

52-Week High 47.69
Last Price 44.87
Fibonacci 61.8% 37.86
Fibonacci 50% 34.83
Fibonacci 38.2% 31.80
52-Week Low 21.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar